1. Indications and Usage
\nPrimary Hyperlipidemia and Mixed Dyslipidemia:
\nIndicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia [HeFH]) or mixed dyslipidemia, to lower LDL-C levels.
\nAtherosclerotic Cardiovascular Disease (ASCVD):
\nIndicated in adults with clinical ASCVD who require additional lowering of LDL-C.
\nLimitation of Use:
\nThe effect of Inclisiran on cardiovascular morbidity and mortality has not been determined.
\n2. Dosage and Administration
\nRoute of Administration:
\nFor Subcutaneous Injection ONLY. (Must be administered by a healthcare professional).
\nRecommended Dosage:
\nDosing Schedule: 284 mg administered as a single subcutaneous injection initially, again at 3 months, and then every 6 months thereafter.
\nMissed Dose:
\nIf missed and within 21 days of the scheduled date: Administer as soon as possible and continue with the original schedule.
\nIf missed and >21 days past the scheduled date: Reschedule for the next available appointment (effectively restarting the 6-month cycle from that point).
\nAdministration Instructions:
\nInject into the abdomen, upper arm, or thigh. Do not inject into areas with active skin disease, lesions, or inflammation.
\n3. Mechanism of Action
\nRNA Interference (RNAi):
\nInclisiran is a double-stranded siRNA that targets PCSK9 messenger RNA (mRNA).
\nIntracellular Inhibition:
\nUnlike monoclonal antibodies (like Alirocumab) that bind to the PCSK9 protein outside the cell, Inclisiran enters liver cells and prevents the production of the PCSK9 protein. This leads to increased recycling of LDL receptors (LDLR) on the hepatocyte surface, thereby lowering circulating LDL-C levels.
\n4. Safety and Warnings
\nHypersensitivity Reactions:
\nHypersensitivity reactions (e.g., rash, urticaria) have been reported. Discontinue if severe.
\nPregnancy:
\nLimited data; use only if clearly needed.
\n5. Adverse Reactions
\nMost Common:
\nInjection site reactions (erythema, pain, swelling, induration), arthralgia, urinary tract infection, diarrhea, bronchitis.
\nComparison to Antibodies:
\nGenerally has a similar safety profile to placebo regarding systemic adverse events, with injection site reactions being the primary concern.
\n6. Drug Interactions
\nStatin Therapy:
\nInclisiran is compatible with statins and does not affect their metabolism. No dose adjustment is required for concomitant use.
\n7. Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Inclisiran Sodium (chemically modified siRNA).
\nAppearance: Clear to slightly opalescent, colorless to pale yellow solution.
\nStorage:
\nStore in a refrigerator at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F).<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u4e50\u53ef\u4e3a\u00ae\uff08Leqvio\u00ae\uff09
\nGeneric Name: Inclisiran Sodium
\nStrength: 284mg\/1.5mL per prefilled syringe, 1 syringe per box
\nManufacturer: Novartis Pharma Stein AG
\nMarketing Authorization Holder: Novartis Pharmaceuticals Co., Ltd.
\nApproval Date in China: 2022
\nRegistration Number: \u56fd\u836f\u51c6\u5b57 HJ20220050
\nStorage: Store at 2\u2103\uff5e8\u2103, avoid freezing and direct light; keep away from children<\/p>\n
Price&Cost:Contact Us now for the best price of Inclisiran Sodium \uff08Leqvio\uff09<\/p>\n","protected":false},"featured_media":3712,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[80],"product_cat":[25],"product_tag":[],"class_list":["post-3711","product","type-product","status-publish","has-post-thumbnail","product_brand-novartis","product_cat-injection","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n